COMMUNIQUÉ DE PRESSE
News
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases
Formycon and Fresenius Kabi secure European Commission approval for FYB202/Otulfi® (ustekinumab) to treat inflammatory diseases, expanding biosimilar portfolio -
-
-
COMMUNIQUÉ DE PRESSE
Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna
Formycon to present clinical data on ustekinumab biosimilar FYB202 at EADV Congress in Amsterdam and UEG Week in Vienna. Biosimilar for psoriasis and IBD in final approval phase
